|
1. Biologie
|
|
|
|
3.1 Tabac
|
|
|
|
|
3.3 Prévention - Vaccins
|
|
|
|
|
|
|
|
|
5. Traitements
|
|
|
Seven of the most promising new approaches in cancer treatment [The Institute of Cancer Research]
|
|
|
|
|
|
Dr
Kukula started by emphasising the major changes there have been in
cancer treatment in recent years — with the move from broad-action
chemotherapy to precision medicines targeted at particular molecular
defects in cancer cells. She then outlined the challenges that remain
even with these treatments — explaining that cancers evolve in a
Darwinian manner, leading to drug resistance, and warning that new
approaches were needed to counter this so-called ‘survival of the
nastiest’.
|
|
|
|
|
|
|
5.12 Immunothérapies
|
|
|
|
All In One Place: A New Immuno-Oncology Trial Resource [Xconomy]
|
|
|
|
|
|
As
reporters, we find that frustrating. Perhaps you do, too. So we’ve
begun this project: a cancer immunotherapy resource that will grow as
the data pool grows. We’re aggregating all the trials we can find that
have patient outcomes: whether a treatment made people better, and for
how long.
|
|
|
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
5.2 Pharma
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
Novartis partners with tiny microcap Cerulean as it nabs $20M [FierceBiotech]
|
|
|
|
|
|
Cerulean’s
tech is intended to create NDCs that selectively attack tumor cells and
reduce toxicity--this is expected to better enable combination therapy.
CRLX101 is still in several ongoing cancer trials in combination with
other cancer treatments; next up is CRLX301, which is in an early stage
trial for advanced solid tumor malignancies.
|
|
|
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
6.5 Médecines alternatives
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
The Cure for Cancer Is Data—Mountains of Data [Wired]
|
|
|
|
|
|
The
New York–based venture will focus on acquiring and expanding companies
that specialize in genetic testing—–think cancer-carrier screenings and
noninvasive prenatal tests—in order to collect and share millions of
individual data sets.
|
|
|